In aggregate, our thorough cross-sectional and longitudinal analyses from the largest series of participants with an FTD syndrome and asymptomatic individuals with a FTD-causing mutation show that plasma NfL consistently outperforms plasma GFAP as a prognostic, susceptibility/risk, and predictive biomarker. Here, NEFL is linked to frontotemporal dementia.